NRXP Expands Access Protocol
NRx Pharmaceuticals announces FDA grant of expanded access protocol for use of D-Cycloserine-based NRX-101 for augmentation of transcranial magnetic stimulation in the treatment of depression
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.